Your SlideShare is downloading. ×
Deepak ppt
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Deepak ppt

223

Published on

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
223
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Presented by: Deepak Sahu (PGDPM) IIHMR Jaipur
  • 2. Aim of project: o To study & analyze the prescription habit of pediatrician for cough preparation. o To find out the mostly prescribed nasal decongestant by pediatrician. o To study & analyze the prescription pattern for respules. o Make the therapy map for children.
  • 3. Research Methodology  Data source primary data source.  Research approach descriptive survey research  Research instruments Questionnaires (multiple choice-closed ended and open ended questions)  Sampling plan a. Sampling unit: b. Sample size: c. Sampling procedures:  Contact method Personal Interview Pediatrician & Chemist 50 pediatrician & 30 chemist simple random sampling
  • 4. Areas covered during survey S.No Area covered No. Of Doctor No. of chemist 1 Sion 3 3 2 Villey parle 3 2 3 Gathkopar 4 3 4 Kalyan 5 4 5 Ullash nagar 3 1 6 Karla 5 4 7 Goregoan 4 3 8 Mulund 6 4 9 Bhandup 8 4 10 Bandra 4 11 Vashi 5 12 Marine line 1 13 Charni road 1 2
  • 5. Objective: To analyze how Paediatrician select the different combinations of cough preparation.
  • 6. Analysis : Prevalence of cough in children 2% 16% (0-5) (5-10) (10-15) 54% 20- more 28%
  • 7. Parameters for Selection of cough Preparations 10% 6% 2% 8% 8% Dose,molecule & Taste Clinical Study Platability, Safety & Side effect Cough History Cough Type Cause & Sine 66%
  • 8. Preferred molecule 4% 40% bronchodilator mucolytic suppressant & bronchodialator other 54% 2%
  • 9. Preferred flavor 22% 30% Mint Strawberry mixed Fruit orange 14% 34% Not specific
  • 10. Preferred parameter 18% Flavour 4% Pack size 2% recommendation 52% 14% Dosage titration Dosage form Price Other 8% 2%
  • 11. Finding & suggestions:  Prevalence of cough in children is more then other      disease. Basic parameters are cough type, cough history & cause. Most preferred molecule is Bronchodilator ,then suppressant. Majority of pediatrician preferred mixed fruits flavor & they are looking for palatability. Basic parameter while choosing any cough preparation are palatability, dose titration & pack size, then later on company & fso. We should organize some camp at dr. clinic for patient eduction.
  • 12. To find out the mostly prescribed nasal decongestant by pediatrician. No. Of patient 8% 8% 38% 10% (0-5) (5-10) (10-15) (15-20) 14% 20< Occasionally 22%
  • 13. Preferred molecule 4% 8% Normal Saline oxymethazone Xylomethazoline 88%
  • 14. Finding & suggestion:  40% of children with urti having nasal congestion.  Majority of Dr. having patient with nasal congetion.  Nasal congestion is the marketing driving molecule.  It takes 88% market share as per Rx wise.  But Xylometazoline & oxymetazoline are market follwing molecule.  This is another huge market for us to expanding the pediatric basket.
  • 15. To study uses of respiratory solution in children % of preference 8% Yes no 92%
  • 16. No. of patients 14% 30% (1-10) 14% (10-20) (20-30) 30-above seasonal 12% 30%
  • 17. Dr. preference to keep stock 42% Yes 58% No
  • 18. Preferred molecule 16% 8% Salbutamol/ levosalbutamol Ipratropium Budisonide Comb 14% 62%
  • 19. % Dr prefer inhalation 28% yes No 72%
  • 20. Market leader: S.No 1. Company Cipla Brand Schemed Percentage Astahlin 16+4 25 Duolin 18+2 10 Levolin 21+4 20
  • 21. Finding & suggestions:  92 % pediatrician prefer nebulization.  30 % of doctor prescribe respules on his routine practice.  58% of doctors are keeping stock of respules in his clinic or nursing home .  62% of Dr. prefer salbutamol & levosalbutamol as first choice for nebulization.  92% of market share is own by Cipla.
  • 22. Therapy map for children
  • 23. Demographic indicator:  Population: 1,029,991,145 (July 2001 EST.)  Age structure: -(0-14) years: 33.12% (male 175,630,537; female 165,540,672) -(15-64 )years: 62.2% (male 331,790,850; female 308,902,864)  Birth rate: 24.28 births/1,000 population (2001 EST.)
  • 24. Indication Total Rx-Jan MAT Rx-Jan MAT 09 10 Rx Grth 120,660 126,757 5 26,147 28,351 8 Diarrhea / Gastroenteritis 14,674 15,447 5 Lower respiratory infection 14,622 15,423 5 Fever 9,130 9,306 2 Viral infection 5,052 6,326 25 Bronchitis 4,450 4,918 11 Respiratory tract infection 2,971 2,650 -11 Acute Pharyngitis 2,810 2,645 -6 Chronic rhinitis / Pharyngitis 1,761 2,317 32 Asthma 2,340 2,261 -3 Abdominal and pelvic pain 2,029 2,175 7 Common cold 2,039 1,901 -7 Cough 1,857 1,876 1 Routine child health examination 1,790 1,822 2 Gastritis and duodenitis 1,640 1,792 9 Acute Respiratory tract infection
  • 25. Avg DrsMAT Jan 09 Specialty Rx-MAT Jan 09 Rx-MAT Jan 10 Rx Grth % Avg DrsMAT Jan 10 Rxer Grth Dispersion P/D-Mar Mat'10 All Doctors 1,493,927 1,576,544 6 228,645 239,579 5 100 548 G.P.(Non MBBS) 382,355 408,611 7 59,646 63,053 6 26.4 540 G.P.(MBBS) 219,344 220,291 0 30,076 29,806 -1 12.3 618 Consulting Physician 129,526 137,582 6 16,590 17,540 6 7.3 655 Dentist 128,010 136,903 7 24,867 26,774 8 11.2 427 Pediatrician 120,660 126,757 5 14,068 14,698 4 6.1 720 Gynecologist 116,450 123,236 6 21,194 21,882 3 9.1 470 Gen.Surgeon 63,176 67,019 6 9,837 10,105 3 4.2 552 Orthopaedic 57,897 62,445 8 9,280 9,845 6 4.1 527 Ophthalmologist 61,211 62,039 1 9,151 9,511 4 4.0 542 ENT Specialist 42,198 45,240 7 6,336 6,643 5 2.8 570 Cardiologist 35,505 38,267 8 5,287 5,611 6 2.3 569 Dermatologist 29,887 31,428 5 4,533 4,739 5 2.0 554 Chest TB Specialist 25,723 28,246 10 3,470 3,776 9 1.6 623 Neurologist Neuro Surgeon 19,049 21,023 10 3,329 3,666 10 1.5 478 Nephrologist Urologist 15,493 16,865 9 2,866 3,074 7 1.3 457 Diabetologist Endocrinologist 13,520 14,803 9 2,204 2,487 13 1.1 493 Psychiatrist 14,048 14,709 5 2,315 2,425 5 1.0 508 Gastroenterologist 13,007 14,167 9 2,241 2,466 10 1.0 475 Oncologist 6,867 6,912 1 1,356 1,481 9 0.6 384
  • 26. Speciality 9 95 9 1 10 10 5 10 0 1 1 11 8 2 2 2 7 3 1 G.P.(Non MBBS) G.P.(MBBS) 7 26 Dentist 4 8 Consulting Physician Paediatrician Gynaecologist 4 Gen.Surgeon 6 Orthopaedic 4 Ophthalmologist ENT Specialist 6 8 Cardiologist 14 Dermatologist 0 8 5 9 7 Chest TB Specialist Neurologist Neuro Surgeon 9 Nephrologist Urologist 6 Diabetologist Endocrinologist Psychiatrist
  • 27. Rx'000-Mar Mat'09 Rx'000PrescriptionsMar Mat'10 Rx Grth P/D-10 Peaadiatric 121,831 127,738 5 720 Anti-Infective 63,835 66,163 4 374 Respiratory 55,613 59,196 6 335 Pain / Analgesics 46,465 49,547 7 281 Others 43,078 45,692 6 261 Gastro Intestinal 31,773 33,842 7 192 Vitamins / Minerals / Nutrients 19,405 19,926 3 115 Derma 8,380 8,421 0 50 Anti-Parasitic 8,180 7,592 -7 47 Hormones 5,495 5,656 3 45 Gynaec. 4,297 4,559 6 31 Neuro / CNS 3,106 3,218 4 23 Anti-Malarials 3,083 2,808 -9 35 Ophthal / Otologicals 2,822 2,725 -3 19 Therapy
  • 28. Acid peptic disease / Acidity / Hyperacidity Conjunctivitis Constipation Chronic sinusitis Urticaria Skin infection Anorexia Typhoid and paratyphoid fevers Otitis media Dehydration Injury COPD Boil / Abscess Wheezing Malaria Acute tonsillitis Acute bronchitis UTI Helminthiases Anaemia Nausea and vomiting immunization Weakness / Malaise and fatigue Gastritis and duodenitis Routine child health examination Cough Common cold Abdominal and pelvic pain Asthma Chronic URTI Acute pharyngitis RTI Bronchitis Viral infection Fever LRTI Diarrhoea / Gastroenteritis Acute URTI 30,000 25,000 20,000 15,000 10,000 5,000 Series1 0 Series2
  • 29. N 2B NON-NARCOTICS,ANTIPYER. J 1D CEPHALOSPORINS R 5B COUGH PREPARATIONS M 1A ANTIRHEUMATIC NONSTR. J 1C AMPICILLIN AMOXYCILLIN R 5A COLD PREPARATIONS R 6A ANTIHISTAMINES,SYSTEMIC J 1F MACROLIDES AND SIMILAR R 3E BRONCHODILATORS LIQUIDS J 1L QUINOLONES A 7K OTH.INCL.LACTIC FERMENT R 1A NASAL DECONGESTANTS A 7L ORAL ELECTROLYTES A 4D ANTIEMET.,ANTINAUS LIQ. A11A MULTIVIT.WITH MINERALS H 2A SYS.CORTICOSTEROIDS PL. A11E VITAMIN B COMPLEX A 2B ANTIPEPTIC ULCERANTS P 1B ANTHELMINTICS EX.SCHIS. A 7G OFLOXACIN COMB. A 3C ANTISPASM.ANTICHOL. COMB. B 3A HAEMATINICS,IRON+COMB A 4C ANTIEMET.,ANTINAUS SOL. A 2A ANTACID,ANTIFLATULENTS A 9A DIGESTIVES INC.ENZYMES P 1D ANTIMALARIALS R 3C BRONCHODIL.INHALANT PREP. A12A CALCIUM PREP. D 6A TOP.ANTIBIOTICS PLAIN J 1K ALL OTHER ANTIBIOTICS R 3D BRONCHODILATORS SOLIDS A 7B NORFLOXACIN COMB. P 1A AMOEBICIDES A11B MULTVIT.WITHOUT MINERALS N 5B TRANQUILIZERS A12C OTHER MINERAL SUPPLEMENT A15A APPETITE STIMULANTS D 2A EMOLLIENTS,PROTECTIVES A 7M OTHER ANTIDIARRHOEALS J 7A PAEDIATRIC SINGLE VACCINE A 5B HEPATIC PROT.LIPOTROPIC S 1A ANTIINFECTIVES J 1E TRIMETHOPRIM COMB.& SIMI. S 2A OTOLOGICALS A 7A PLAIN INTEST.ANTIINFECT. A 4F ANTIEMET.,ANTINAUS COMB. 35,000 30,000 25,000 20,000 15,000 10,000 5,000 0
  • 30. 25,000 Major Player 20,000 15,000 10,000 Series1 Series2 5,000 0
  • 31. Market driving molecules: 30,000 25,000 20,000 15,000 10,000 Series1 5,000 0 Series2
  • 32. Top 20molecule with growing trend
  • 33. S.n o Subgroup 1 Cepodoxime oral liq. 11147 33 2 Cefixime oral solid 52945 3 Cefpodoxime oral solid 4 MAT Mar 10 Value Grth Unit Grth (Value) (MAT Mar 10) (MAT Mar 10) Rx share% RX Grw% P/D Rx 33 16 7 41 23 29 13 11 35 27429 32 31 13 18 39 Cefixime oral liq. 9235 15 22 10 21 28 5 Cefadroxil oral liq. 2052 -1 -2 7 -21 24 6 Cefadroxil oral solid 13248 -8 0 6 -9 24 7 Amoxy & Clav.liq 15270 33 41 40 16 53 8 Amoxy & Clav.solid 36532 35 52 17 27 31 9 Amoxy solid 24106 10 -4 15 -5 36 10 Amoxy liq 6639 7 -1 13 -8 35 11 Azithromycin oral liq 31650 28 26 47 9 44 12 Azithromycin oral solid 5623 44 36 31 34 32 13 Erythromycin Liq 2360 14 16 5 10 17 14 Erythromycinoral solid 7406 7 9 5 -18 16
  • 34. S.n o Subgroup 15 MAT Mar 10 Value Grth Unit Grth (MAT (Value) (MAT Mar 10) Mar 10) Rx share% RX Grw% P/D Rx RANITIDINE ORAL SOLIDS 24528 12 -5 18 11 16 LANSOPRAZOLE 2016 14 2 15 36 19 PANTOPR.+ DOMPERID. 17763 33 26 10 91 22 PANTOPRAZOLE SOLIDS 18948 20 15 9 55 13 ORAL ELECTROLYTES 14597 27 17 85 10 48 Nasal Decongestant 13592 30 22 13 8 55 16 17 18 19 20
  • 35. Thank You

×